Results 81 to 90 of about 56,104 (259)
Lichen Planus Following COVID‐19 Infection and Vaccination. Matched Case–Control Study
ABSTRACT Background New‐onset lichen planus (LP) development following COVID‐19 infection/vaccination is reported. Since case series cannot be used to study exposure–outcome associations, we designed this matched case–control study to investigate whether COVID‐19‐related events and de novo LP are associated.
Paolo Giacomo Arduino+4 more
wiley +1 more source
Data were included from adolescents with moderate‐to‐severe AD treated with the JAK1 inhibitor abrocitinib (200 mg/100 mg) across JADE clinical trials. Improvements in skin clearance (per EASI‐75) and itch (per PP‐NRS4) were maintained for up to 112 weeks with both abrocitinib doses.
Amy S. Paller+13 more
wiley +1 more source
Herpesvaricellae-zoster virus (VZV) on alfaherpesviiruste hulka kuuluv kaheahelaline DNA-viirus, mis põhjustab inimestel primaarinfektsioonina tuulerõugeid (varicella) ja sekundaarse infektsioonina vöötohatist (herpes zoster).
Puis, Liis
core +2 more sources
Update on andrological effects of SARS‐CoV‐2 infection and COVID‐19: An overview review
Abstract Background Evidence indicates a wide range of andrological alterations in patients with the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS‐CoV‐2) infection and Coronavirus Disease 2019 (COVID‐19). Aim To provide an update on the andrological effects of SARS‐CoV‐2 infection and COVID‐19.
Giuseppe Lisco+7 more
wiley +1 more source
Vaccines for prophylaxis of viral infections in patients with hematological malignancies. [PDF]
Viral infections cause significant morbidity and mortality in patients with hematological malignancies. It remains uncertain whether viral vaccinations in these patients are supported by good evidence.
Chan, GC+4 more
core +1 more source
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
In total 169 patients already exposed to a JAKi and who received a second JAKi were retrospectively studied across 28 GETAID centres, with 48% reaching steroids‐free clinical remission after induction. Adverse events led to treatment discontinuation in 5% of cases.
Mathilde Osty+56 more
wiley +1 more source
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M+4 more
core
Summary The immunosuppressive and immunomodulatory treatment of dermatological patients necessitates the regular review and updating of standard vaccinations and vaccines indicated for specific conditions. The German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute regularly publishes evidence‐based vaccination recommendations ...
Johanna Stoevesandt+3 more
wiley +1 more source
Study of the Clinical Patterns in Varicella in a Tertiary Hospital at Coastal Karnataka [PDF]
Context: There are very few studies regarding the clinical patterns and manifestations of a very common viral infection, Varicella, especially from south India.
Girish, PN+3 more
core
Risk of Herpes Zoster in Individuals on Biologics, DMARDS and/or Corticosteroids for Autoimmune Diseases:A Systematic Review and Meta-Analysis [PDF]
Background: Studies examining the risk of herpes zoster (HZ) associated with immunosuppressants, such as biologics, non-biological disease modifying agents (nbDMARDs) or corticosteroids, have generated conflicting results.
Alarcón-Segovia+94 more
core +1 more source